Aug 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Xdemvy lotilaner 7/25/2023 To treat Demodex blepharitis Vanflyta quizartinib

Jul 052023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Ngenla somatrogon-ghla 6/27/2023 To treat growth failure due to

Jun 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Inpefa sotagliflozin 5/26/2023 To treat heart failure Drug Trials

Apr 032023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Joenja leniolisib 3/24/2023 To treat activated phosphoinositide 3-kinase delta

Mar 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Skyclarys omaveloxolone 2/28/2023 To treat Friedrich’s ataxia Drug Trials

Feb 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Orserdu elacestrant 1/27/2023 To treat estrogen receptor-positive, human epidermal

Jan 032023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot NexoBrid anacaulase-bcdb 12/28/2022 To remove eschar in adults with

Dec 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Tzield teplizumab-mzwv 11/18/2022 To delay the onset of stage

Nov 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Tecvayli teclistamab-cqyv 10/25/2022 To treat relapsed or refractory multiple

Oct 032022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Lytgobi futibatinib 9/30/2022 To treat intrahepatic cholangiocarcinoma harboring fibroblast